This study aims to test the safety and how well people handle a new drug called PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1). DM1 is a muscle disorder caused by a problem in the DMPK gene. The study lasts about 16 weeks, with a screening time of up to 30 days. During the study, participants will receive one dose of the drug through a vein (IV).
What to Know:
- Time Commitment: Screening can take up to 30 days, and the study itself is 16 weeks long.
- Eligibility: Participants need a confirmed DM1 diagnosis with certain gene repeats and muscle strength requirements.
- Exclusions: Those with certain health conditions or who have taken specific medications recently may not qualify.
Participants should weigh the commitment and eligibility criteria before deciding to join. As with any study, there may be risks involved, so discussing with a healthcare provider is recommended.
How understandable was the trial content above?
Hard to understand
Easy to understand